[1. Klein R, Klein BE, Moss S, DeMets DL. Proteinuria in diabetes. Arch Intern Med. 1988; 148:181-6.10.1001/archinte.1988.00380010183019]Search in Google Scholar
[2. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998; 128:982-8.10.7326/0003-4819-128-12_Part_1-199806150-00004]Search in Google Scholar
[3. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006; 4:CD006257.10.1002/14651858.CD006257695664617054288]Search in Google Scholar
[4. Sakthong P, Tangphao O, Eiam-ong S, Kamolratanakul P, Supakankunti S, Himathongkam T, et al. Costeffectiveness of using angiotensin-converting enzyme inhibitors to slow nephropathy in normotensive patients with diabetes type II and microalbuminuria. Nephrology. 2001; 6:71-7.10.1046/j.1440-1797.2001.00036.x]Open DOISearch in Google Scholar
[5. Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, et al. The CARI guidelines. Costeffectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes. Nephrology. 2010; 15(Suppl 1): S195-203.10.1111/j.1440-1797.2010.01239.x20591027]Search in Google Scholar
[6. Rippin JD, Barnett AH, Bain SC. Cost-effective strategies in the prevention of diabetic nephropathy. Pharmacoeconomics. 2004; 22:9-28.10.2165/00019053-200422010-0000214720079]Open DOISearch in Google Scholar
[7. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63:225-32.10.1046/j.1523-1755.2003.00712.x12472787]Open DOISearch in Google Scholar
[8. Krairittichai U, Potisat S, Jongsareejit A, Sattaputh C. Accuracy of urine dipstick test for microalbuminuria in type 2 diabetes mellitus patients. J Med Assoc Thai. 2011; 94 Suppl 2:S6-10.]Search in Google Scholar
[9. Lepore G, Maglio ML, Nosari I, Dodesini AR, Trevisan R. Cost-effectiveness of two screening programs for microalbuminuria in type 2 diabetes. Diabetes Care. 2002; 25:2103-4.10.2337/diacare.25.11.210312401764]Search in Google Scholar
[10. United Nation Thailand. Thailand Info [internet] 2010 [cited 2011 Jun 18]. Available from: http://www.un.or.th/thailand.]Search in Google Scholar
[11. National Health Security Office. Annual report of Thai Universal Health Coverage Scheme 2009. Bangkok: Sahamitr Printing and Publishing; 2010.]Search in Google Scholar
[12. Zhang AH, Cheng LT, Zhu N, Sun LH, Wang T. Comparison of quality of life and causes of hospitalization between hemodialysis and peritoneal dialysis patients in China. Health Qual Life Outcomes. 2007; 5:49.10.1186/1477-7525-5-49198878817678543]Search in Google Scholar
[13. Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol. 2004; 15:3117-25.10.1097/01.ASN.0000146423.71226.0C15579515]Search in Google Scholar
[14. McIntosh A, Hutchinson A, Marshall S, Barnes D, Brown V, Hopper S, et al. Clinical guidelines and evidence review for type 2 diabetes. Renal disease: prevention and early management. Sheffield: ScHARR, University of Sheffield; 2002.10.1177/14746514020020041401]Search in Google Scholar
[15. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998; 13:397-409.10.2165/00019053-199813040-00003]Open DOISearch in Google Scholar
[16. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005; 143:89-99.10.7326/0003-4819-143-2-200507190-00007]Search in Google Scholar
[17. Ministry of Public Health, Thailand. Public health statistics 2010 [Internet] 2010 [cited 2011 Jun 18]. Available from: http://bps.ops.moph.go.th/Healthinformation/statistic53/statistic53.pdf.]Search in Google Scholar
[18. Groop PH, Thomas MC, Moran JL, Wad☐n J, Thorn LM, M☐kinen VP, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009; 58:1651-8.10.2337/db08-1543]Open DOISearch in Google Scholar
[19. Pratipanawatr T, Rawdaree P, Chetthakul T, Bunnag P, Ngarmukos C, Benjasuratwong Y, et al. Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death. J Med Assoc Thai. 2010; 93(Suppl 3):S12-20.]Search in Google Scholar
[20. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.]Search in Google Scholar
[21. Tongsiri S, Cairns J. Estimating population-based values for EQ-5D health states in Thailand. Value Health. 2011; 14:1142-5.10.1016/j.jval.2011.06.005]Open DOISearch in Google Scholar
[22. World Health Organization. Choosing interventions that are cost-effective (WHO-CHOICE): costeffectiveness thresholds [internet] 2005 [cited 2011 Aug 24]. Available from: http://www.who.int/choice/costs/CER_levels/en/index.html.]Search in Google Scholar
[23. The World Bank. GDP per capita (current US$) [internet] 2011 [cited 2012 Aug 24]. Available from: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.]Search in Google Scholar
[24. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17:2937-44.10.1681/ASN.2006040368]Open DOISearch in Google Scholar
[25. Thaweethamcharoen T, Sakulbumrungsil R, Vasuvattakul S, Nopmaneejumruslers C. Comparison of SF-6D, EQ-5D and VAS in hemodialysis Thai patients. Value Health. 2010; 13:A567.10.1016/S1098-3015(11)73384-8]Open DOISearch in Google Scholar
[26. Liem YS, Bosch JL, Hunink MG. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value Health. 2008; 11:733-41.10.1111/j.1524-4733.2007.00308.x18194399]Open DOISearch in Google Scholar
[27. Thavorncharoensap M, Teerawattananon Y, Natanant S, Werayingyong P, Yothasamut J, Putchong C, et al. Assessing a societal value for a ceiling threshold in Thailand. Nonthaburi, Thailand: Health Intervention and Technology Assessment Program; 2009.]Search in Google Scholar
[28. Kessler R, Keusch G, Szucs TD, Wittenborn JS, Hoerger TJ, Brugger U, et al. Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland. Swiss Med Wkly. 2012; 142: w13508.10.4414/smw.2012.1350822307760]Search in Google Scholar
[29. Siegel JE, Krolewski AS, Warram JH, Weinstein MC. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol. 1992; 3(4 Suppl): S111-9.10.1681/ASN.V34s1111457753]Search in Google Scholar
[30. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ. 1995; 311:1595-9.10.1136/bmj.311.7020.1595]Search in Google Scholar
[31. Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant. 2008; 23:1216-23.10.1093/ndt/gfn082]Search in Google Scholar
[32. Palmer AJ, Chen R, Valentine WJ, Roze S, Bregman B, Mehin N, et al. Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes. Diabetes Metab. 2006; 32:69-76.10.1016/S1262-3636(07)70249-5]Open DOISearch in Google Scholar
[33. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003; 290:3101-14.10.1001/jama.290.23.310114679273]Search in Google Scholar
[34. Howard K, White S, Salkeld G, McDonald S, Craig JC, Chadban S, et al. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. Value Health. 2010; 13:196-208.10.1111/j.1524-4733.2009.00668.x19878493]Open DOISearch in Google Scholar
[35. Kiberd BA, Jindal KK. Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure? Mayo Clin Proc. 1999; 74:559-64.10.4065/74.6.55910377929]Open DOISearch in Google Scholar
[36. Golan L, Birkmeyer JD, Welch HG. The costeffectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999; 131:660-7.10.7326/0003-4819-131-9-199911020-0000510577328]Search in Google Scholar